BioCryst Pharmaceuticals BCRX Collaborative and other revenues — Total revenues

Similar metrics at other companies

RCUSOther collaboration — Total revenues

$5M-37.5%

TARSLicense fees and collaboration revenue — Total revenues

$16.67M—

CRNXCollaboration and license revenue — Total Revenue

$428K+18.6%

NBIXCollaboration revenues — Total revenues

$3.5M-60.7%

EXELCollaboration — Total revenues

$55.84M+32.4%

LLYCollaboration and Other Revenue — Revenue

$1.35B+19.4%

Questions, answered.

What is BioCryst Pharmaceuticals's collaborative and other revenues — total revenues?

BioCryst Pharmaceuticals (BCRX) reported collaborative and other revenues — total revenues of $2M in Q1 2026.

How has BioCryst Pharmaceuticals's collaborative and other revenues — total revenues changed year-over-year?

BioCryst Pharmaceuticals's collaborative and other revenues — total revenues increased by 14.3% year-over-year, from $1.75M to $2M.

What is the long-term trend for BioCryst Pharmaceuticals's collaborative and other revenues — total revenues?

Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's collaborative and other revenues — total revenues has grown at a -22.0% compound annual growth rate (CAGR), from $20.82M to $7.71M.

What does collaborative and other revenues — total revenues mean?

This metric represents the total revenue generated from collaborative research agreements, licensing arrangements, and other non-product-based development activities. It reflects the company's ability to monetize its intellectual property and scientific expertise through partnerships with third-party organizations. This revenue stream is critical for assessing the value of the company's research pipeline and its success in securing external funding for drug development programs.